UK markets open in 3 hours 51 minutes

Clinuvel Pharmaceuticals Limited (CUV.XA)

Cboe AU - Cboe AU Real-time price. Currency in AUD
Add to watchlist
15.37-0.37 (-2.35%)
As of 01:08PM AEST. Market open.
Currency in AUD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.92
52-week change 3-8.83%
S&P500 52-week change 324.96%
52-week high 321.43
52-week low 312.98
50-day moving average 315.10
200-day moving average 315.50

Share statistics

Avg vol (3-month) 310.61k
Avg vol (10-day) 39.14k
Shares outstanding 5N/A
Implied shares outstanding 6N/A
Float 839.49M
% held by insiders 120.44%
% held by institutions 18.94%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.05
Trailing annual dividend yield 30.32%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Jun 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 36.88%
Operating margin (ttm)42.37%

Management effectiveness

Return on assets (ttm)14.71%
Return on equity (ttm)18.98%

Income statement

Revenue (ttm)81.76M
Revenue per share (ttm)1.65
Quarterly revenue growth (yoy)11.70%
Gross profit (ttm)N/A
EBITDA 44.36M
Net income avi to common (ttm)30.15M
Diluted EPS (ttm)0.47
Quarterly earnings growth (yoy)-4.00%

Balance sheet

Total cash (mrq)174.45M
Total cash per share (mrq)3.52
Total debt (mrq)1.07M
Total debt/equity (mrq)0.60%
Current ratio (mrq)6.86
Book value per share (mrq)3.61

Cash flow statement

Operating cash flow (ttm)42.27M
Levered free cash flow (ttm)31.29M